Of note, bufalin has also been reported to inhibit AR activation by suppressing the steroid receptor co-activator SRC-3 without binding to the receptor itself37, suggesting the key role of AR in bufalin-induced HCC suppression. Here, NCOA3 is linked to hepatocellular carcinoma.